Haven't posted for over a year, from memory... just been content to read.... however these results are demonstrably good.
The LOW patient numbers are often seen to have a weakening effect on the impact of the results, however I view this as more of a positive than a negative. Merck and others have several hundred Trials in progress at any one time. They are in a position to choose as many early stage patients as possible... thus increasing their chances of better results. Cavatak has had to serve a lengthy apprenticeship using a high percentage of the very patients that others would want to keep out of their Trials.... the dreaded Stage 4 unfortunates ( the wqlking dead).
I would think that getting great results from a pitiful number of "nothing to lose"patients has more impact than reasonable results from a large number of early stage sufferers.
Also, the above applies to Cavatak in combination with TWO drugs controlled by Pharmas... so far... and I wonder how many others there are out there which would deliver similar results when combined with Cavatak.
Surely these results will open a few more eyes.
VLA Price at posting:
$1.26 Sentiment: Buy Disclosure: Held
